Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug 25;60(2):2201227.
doi: 10.1183/13993003.01227-2022. Print 2022 Aug.

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

Tiziana Masini  1 , Avinash Kanchar  2 , Fuad Mirzayev  2 , Kerri Viney  2 , Askar Yedilbayev  3 , Matteo Zignol  2 , Dennis Falzon  2
Affiliations
Comment

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

Tiziana Masini et al. Eur Respir J. .

Abstract

Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: All authors have nothing to disclose.

Comment on

  • Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
    Guglielmetti L, Günther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL, Goletti D, Jankovic M, Kuksa L, Maurer FP, Méchaï F, Tiberi S, van Leth F, Veziris N, Lange C; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet). Guglielmetti L, et al. Eur Respir J. 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022. Print 2022 May. Eur Respir J. 2022. PMID: 35589114 Free PMC article.

References

    1. Guglielmetti L, Günther G, Leu C, et al. . Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J 2022; 59: 2200388. doi:10.1183/13993003.00388-2022 - DOI - PMC - PubMed
    1. World Health Organization . WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention – Tuberculosis Preventive Treatment. Geneva, World Health Organization, 2020. - PubMed
    1. World Health Organization . WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment – Drug-Susceptible Tuberculosis Treatment. Geneva, World Health Organization, 2022. - PubMed
    1. World Health Organization . WHO TB Knowledge Sharing Platform. Date last accessed: 13 June 2022. https://extranet.who.int/tbknowledge
    1. World Health Organization . Model List of Essential Medicines. 22nd list, 2021. https://apps.who.int/iris/rest/bitstreams/1374779/retrieve